Automated Workflows for Mass, Purity and Sequence Analysis of Oligonucleotides
Oligonucleotide therapeutics have emerged in recent years as a powerful alternative to small molecule and protein therapeutics. Manufacturing and quality control of oligonucleotide therapeutics requires highly selective and sensitive LC-MS methods.
This presentation will highlight two recently introduced software applications:
INTACT Mass which enables rapid intact mass confirmation of oligonucleotides and their impurities
CONFIRM Sequence which enables rapid sequence confirmation of oligonucleotides and their impurities through automated analysis of MS fragmentation spectra.
These two applications are fully integrated into our compliance-ready waters_connect informatics platform and work together to provide a modern end-to-end solution for oligonucleotides analysis.
Key Learning Objectives
How end-to-end workflows with automated data processing, analysis and reporting accelerate oligonucleotide development and enhance productivity.
How a scalable compliance-ready network of high-resolution LC-MS workflows can streamline operations, reduce training and enhance competitiveness.
How new INTACT Mass and CONFIRM Sequence apps on the waters_connect platform speed characterization, attribute monitoring and QC release.
Who should attend
Lab Directors and Managers expanding operations in the oligonucleotide / nucleic-acid therapeutic space.
Analytical Development and Quality Control Scientists focused on oligonucleotide characterization and CMC
GMP Process and Formulation Development Scientists working with oligonucleotide / nucleic-acid therapeutics
Presenter: Catalin Doneanu PhD. (Principal Scientist, Waters Corporation)
Catalin Doneanu received his Ph.D. in analytical chemistry from Oregon State University in 2002. After a postdoctoral stage in the Department of Medicinal Chemistry at University of Washington in Seattle, he joined Waters Corporation in 2006. He is currently a principal scientist in the Biopharmaceutical Sciences group. He has more than twenty years of experience in separation sciences and mass spectrometry. His current research interests are in the area of therapeutic oligonucleotides and protein characterization using LC-MS. Catalin has over 30 peer-reviewed publications.
Presenter: Joe Fredette (Senior Business Development Manager, Waters Corporation)
Joe Fredette is a Senior Business Development Manager at Waters and global marketing lead for Nucleic Acid Therapeutics / New Modalities. He joined Waters in 2014, bringing with him more than 25 years of life science industry experience, including product & strategic marketing leadership roles at Corning Life Sciences, Caliper Life Sciences, Millipore and Thermo Fisher Scientific. In his current role he leads a cross-functional team focused on delivering robust applications, tools and solutions for nucleic acid therapeutic development, manufacturing and QC release. Joe received a B.S. in Microbiology from Cornell University.
